BioMarin to Participate at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England


Werte in diesem Artikel
Aktien

52.18 EUR -0.28 EUR -0.53 %

SAN RAFAEL, Calif., Nov. 11, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 10:30 AM GMT in London, England in London.

BioMarin Pharmaceutical logo (PRNewsfoto/BioMarin Pharmaceutical Inc.)

An audio webcast of the presentation will be available live. The webcast can be accessed at: https://investors.biomarin.com/. An archived version of the remarks will also be available through the Company's website for a limited time following the conference. 

About BioMarin
BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The San Rafael, California-based company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin pursues treatments that offer new possibilities for patients and families around the world navigating rare or difficult-to-treat genetic conditions. To learn more, please visit www.biomarin.com.

Contacts:


Investors                           

Media

Traci McCarty                   

Marni Kottle

BioMarin Pharmaceutical Inc.               

BioMarin Pharmaceutical Inc.

(415) 455-7558                                       

(650) 374-2803

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/biomarin-to-participate-at-the-jefferies-global-healthcare-conference-on-tuesday-november-18-2025-at-1030-am-gmt-in-london-england-302610867.html

SOURCE BioMarin Pharmaceutical Inc.

Aktuelle Biomarin Pharmaceutical Aktie News

Werbung

Biomarin Pharmaceutical Analysen

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Biomarin Pharmaceutical nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
DatumRatingAnalyst
14.12.18 Biomarin Pharmaceutical Outperform Wolfe Research
01.10.18 Biomarin Pharmaceutical Overweight Cantor Fitzgerald
07.08.18 Biomarin Pharmaceutical Buy Stifel, Nicolaus & Co., Inc.
03.08.18 Biomarin Pharmaceutical Buy Stifel, Nicolaus & Co., Inc.
16.05.18 Biomarin Pharmaceutical Buy Canaccord Adams